`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`ELI LILLY AND COMPANY
`Petitioner
`
`v.
`
`TEVA PHARMACEUTICALS INTERNATIONAL GMBH
`Patent Owner
`
`_____________________
`
`Case IPR2018-01423
`U.S. Pat. No. 9,266,951
`_____________________
`
`TEVA PHARMACEUTICALS INTERNATIONAL
`GMBH’S MANDATORY NOTICES
`
`
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`Patent Owner, Teva Pharmaceuticals International GmbH, hereby files
`
`IPR2018-01423
`U.S. Patent No. 9,266,951
`
`mandatory notices pursuant to 37 C.F.R. § 42.8(a)(2).
`
`A. Real Parties in Interest (37 C.F.R. § 42.8(b)(1))
`
`The real parties-in-interest are Teva Pharmaceuticals International GmbH and
`
`Teva Pharmaceuticals USA, Inc.
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2))
`
` Patent Owner notes the following judicial matters that may affect or be
`
`affected by a decision in this proceeding:
`
` Teva Pharmaceuticals International GmbH v. Eli Lilly and Company,
`
`Civ. No. 1-17-cv-12087 (D. Mass);
`
` Teva Pharmaceuticals International GmBH v. Eli Lilly and Company,
`
`Civ. No. 1-18-cv-10242 (D. Mass.);
`
` Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
`
`IPR2018-01422;
`
` Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
`
`IPR2018-01424;
`
` Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
`
`IPR2018-01425;
`
`
`
`IPR2018-01423
`U.S. Patent No. 9,266,951
` Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
`
`IPR2018-01426; and
`
` Eli Lilly and Company v. Teva Pharmaceuticals International GmbH
`
`IPR2018-01427.
`
`Patent Owner identifies the following patents and applications to which the
`
`U.S. Patent No. 9,266,951 (“the ’951 patent”) claims the benefit of an earlier priority
`
`filing date or which shares the benefit of an earlier priority filing date with the ’951
`
`patent:
`
` U.S. Patent No. 9,890,211;
`
` U.S. Patent No. 9,890,210;
`
` U.S. Patent No. 9,884,908;
`
` U.S. Patent No. 9,884,907;
`
` U.S. Patent No. 9,365,648;
`
` U.S. Patent No. 9,346,881;
`
` U.S. Patent No. 9,340,614;
`
` U.S. Patent No. 9,328,168;
`
` U.S. Patent No. 9,115,194;
`
` U.S. Patent No. 8,734,802;
`
` U.S. Patent No. 8,597,649;
`
`
`
` U.S. Patent No. 8,586,045;
`
` U.S. Patent No. 8,007,794;
`
`IPR2018-01423
`U.S. Patent No. 9,266,951
`
` U.S. Application No. 15/883,218 (pending); and
`
` U.S. Application No. 15/956,580 (pending).
`
`Patent Owner does not concede that the identified patents or applications
`
`would affect, or be affected by, a decision in the present inter partes review.
`
`C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3))
`
`Patent Owner designates the following lead and back-up counsel:
`
` Deborah A. Sterling (Reg. No. 62,732) phone:202.772.8501
`Lead Counsel:
`Back-up Counsel: Robert C. Millonig (Reg. No. 34,395) phone:202.371.2600
`
`
` Gaby L. Longsworth (Reg. No. 47,756) phone: 202.371.2600
` Jeremiah B. Frueauf (Reg. No. 66,638) phone: 202.371.2600
`
`Address:
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`1100 New York Avenue, NW
`Washington, DC 20005
`202.371.2600 (reception)
`202.371.2540 (facsimile)
` dsterling-PTAB@sternekessler.com
`
`
`
`bobm-PTAB@sternekessler.com
`
`
`
`glongs-PTAB@sternekessler.com
`jfrueauf-PTAB@sternekessler.com
`
`
`
`
`
`
`
`
`
`
`
`IPR2018-01423
`U.S. Patent No. 9,266,951
`Service Information (37 C.F.R. § 42.8(b)(4))
`
`D.
`
`Patent Owner consents to electronic service by email. Please direct all
`
`correspondence regarding this proceeding to the lead and back-up counsel at the
`
`addresses listed above.
`
` The Patent Trial and Appeal Board is hereby authorized to charge any fees
`
`associated with this proceeding to Deposit Account 19-0036 (Customer ID
`
`No. 45324).
`
` Respectfully Submitted,
` STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
`
` Deborah Sterling, Ph.D.
`Date: August 29, 2018
` Lead Attorney for Patent Owner
`
`
`
`
`
`1100 New York Avenue, N.W. Registration No. 62,732
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`
`
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`
`
`The undersigned hereby certifies that the above-captioned “Teva
`
`Pharmaceuticals International GmbH’s Mandatory Notices” was served in its
`
`entirety on August 29, 2018, upon the Petitioner via e-mail:
`
`Sanjay M. Jivraj
`Mark J. Stewart
`Eli Lilly and Company
`Lilly Corporate Center Patent Dept.
`Indianapolis, IN 46285
`jivraj_sanjay@lilly.com
`stewart_mark@lilly.com
`
`William B. Raich
`Erin M. Sommers
`Pier D. DeRoo
`Yieyie Yang
`Finnegan, Henderson, Farabow,
`Garrett & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`william.raich@finnegan.com
`erin.sommers@finnegan.com
`pier.deroo@finnegan.com
`yieyie.yang@finnegan.com
`
`
`
`
` STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
`
` Deborah Sterling, Ph.D.
`Date: August 29, 2018
` Lead Attorney for Patent Owner
`
`
`
`
`
`1100 New York Avenue, N.W. Registration No. 62,732
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`9815567.1
`
`